Q-omics provides the consensus-scored TMEM102 profile across patient tissues and cancer cell-line models. TMEM102 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM102 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TMEM102 RNA expression shows 15,570 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where TMEM102 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM102 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM102 survival associations across molecular data types. TMEM102 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM102 RNA expression–survival associations across cancer types. High TMEM102 expression shows unfavorable associations in LGG and LUAD, but favorable associations in KIRC, STAD, MESO and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM102 RNA expression.
This table summarizes TMEM102 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM102. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM102 shows lower tumor expression in KICH and higher tumor expression in KIRC, BLCA, HNSC, UCEC and KIRP. The KIRC box plot shows higher TMEM102 RNA expression in tumor versus normal tissue (log2 FC = +0.470, t-test p < 0.001).
This table shows molecular features associated with TMEM102 in patient tissues and cancer cell lines. In patient samples, TMEM102 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM102 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
